Development of consensus-driven SPIRIT and CONSORT extensions for early phase dose-finding trials: the DEFINE study.
CONSORT guideline
SPIRIT guideline
clinical trials
dose finding
early phase
Journal
BMC medicine
ISSN: 1741-7015
Titre abrégé: BMC Med
Pays: England
ID NLM: 101190723
Informations de publication
Date de publication:
05 07 2023
05 07 2023
Historique:
received:
04
04
2023
accepted:
12
06
2023
medline:
7
7
2023
pubmed:
6
7
2023
entrez:
5
7
2023
Statut:
epublish
Résumé
Early phase dose-finding (EPDF) trials are crucial for the development of a new intervention and influence whether it should be investigated in further trials. Guidance exists for clinical trial protocols and completed trial reports in the SPIRIT and CONSORT guidelines, respectively. However, both guidelines and their extensions do not adequately address the characteristics of EPDF trials. Building on the SPIRIT and CONSORT checklists, the DEFINE study aims to develop international consensus-driven guidelines for EPDF trial protocols (SPIRIT-DEFINE) and reports (CONSORT-DEFINE). The initial generation of candidate items was informed by reviewing published EPDF trial reports. The early draft items were refined further through a review of the published and grey literature, analysis of real-world examples, citation and reference searches, and expert recommendations, followed by a two-round modified Delphi process. Patient and public involvement and engagement (PPIE) was pursued concurrently with the quantitative and thematic analysis of Delphi participants' feedback. The Delphi survey included 79 new or modified SPIRIT-DEFINE (n = 36) and CONSORT-DEFINE (n = 43) extension candidate items. In Round One, 206 interdisciplinary stakeholders from 24 countries voted and 151 stakeholders voted in Round Two. Following Round One feedback, one item for CONSORT-DEFINE was added in Round Two. Of the 80 items, 60 met the threshold for inclusion (≥ 70% of respondents voted critical: 26 SPIRIT-DEFINE, 34 CONSORT-DEFINE), with the remaining 20 items to be further discussed at the consensus meeting. The parallel PPIE work resulted in the development of an EPDF lay summary toolkit consisting of a template with guidance notes and an exemplar. By detailing the development journey of the DEFINE study and the decisions undertaken, we envision that this will enhance understanding and help researchers in the development of future guidelines. The SPIRIT-DEFINE and CONSORT-DEFINE guidelines will allow investigators to effectively address essential items that should be present in EPDF trial protocols and reports, thereby promoting transparency, comprehensiveness, and reproducibility. SPIRIT-DEFINE and CONSORT-DEFINE are registered with the EQUATOR Network ( https://www.equator-network.org/ ).
Sections du résumé
BACKGROUND
Early phase dose-finding (EPDF) trials are crucial for the development of a new intervention and influence whether it should be investigated in further trials. Guidance exists for clinical trial protocols and completed trial reports in the SPIRIT and CONSORT guidelines, respectively. However, both guidelines and their extensions do not adequately address the characteristics of EPDF trials. Building on the SPIRIT and CONSORT checklists, the DEFINE study aims to develop international consensus-driven guidelines for EPDF trial protocols (SPIRIT-DEFINE) and reports (CONSORT-DEFINE).
METHODS
The initial generation of candidate items was informed by reviewing published EPDF trial reports. The early draft items were refined further through a review of the published and grey literature, analysis of real-world examples, citation and reference searches, and expert recommendations, followed by a two-round modified Delphi process. Patient and public involvement and engagement (PPIE) was pursued concurrently with the quantitative and thematic analysis of Delphi participants' feedback.
RESULTS
The Delphi survey included 79 new or modified SPIRIT-DEFINE (n = 36) and CONSORT-DEFINE (n = 43) extension candidate items. In Round One, 206 interdisciplinary stakeholders from 24 countries voted and 151 stakeholders voted in Round Two. Following Round One feedback, one item for CONSORT-DEFINE was added in Round Two. Of the 80 items, 60 met the threshold for inclusion (≥ 70% of respondents voted critical: 26 SPIRIT-DEFINE, 34 CONSORT-DEFINE), with the remaining 20 items to be further discussed at the consensus meeting. The parallel PPIE work resulted in the development of an EPDF lay summary toolkit consisting of a template with guidance notes and an exemplar.
CONCLUSIONS
By detailing the development journey of the DEFINE study and the decisions undertaken, we envision that this will enhance understanding and help researchers in the development of future guidelines. The SPIRIT-DEFINE and CONSORT-DEFINE guidelines will allow investigators to effectively address essential items that should be present in EPDF trial protocols and reports, thereby promoting transparency, comprehensiveness, and reproducibility.
TRIAL REGISTRATION
SPIRIT-DEFINE and CONSORT-DEFINE are registered with the EQUATOR Network ( https://www.equator-network.org/ ).
Identifiants
pubmed: 37408015
doi: 10.1186/s12916-023-02937-0
pii: 10.1186/s12916-023-02937-0
pmc: PMC10324137
doi:
Types de publication
Review
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
246Subventions
Organisme : Cancer Research UK
ID : NACDDP-SEP22/100001
Pays : United Kingdom
Organisme : Cancer Research UK
ID : 29827
Pays : United Kingdom
Organisme : Cancer Research UK
ID : 18182
Pays : United Kingdom
Organisme : Cancer Research UK
ID : 12946
Pays : United Kingdom
Organisme : Department of Health
Pays : United Kingdom
Organisme : Cancer Research UK
ID : 20850
Pays : United Kingdom
Organisme : Cancer Research UK
ID : 20409
Pays : United Kingdom
Organisme : NCATS NIH HHS
ID : UL1 TR001873
Pays : United States
Organisme : Cancer Research UK
ID : 11650
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/T044934/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UU_00002/14
Pays : United Kingdom
Informations de copyright
© 2023. The Author(s).
Références
Nat Rev Clin Oncol. 2013 May;10(5):277-88
pubmed: 23507740
Br J Clin Pharmacol. 2018 Jul;84(7):1401-1409
pubmed: 29451320
Drug Des Devel Ther. 2016 Dec 08;10:4005-4016
pubmed: 27994442
BMJ Open. 2023 Mar 29;13(3):e068173
pubmed: 36990492
J Natl Cancer Inst. 2019 Feb 1;111(2):118-128
pubmed: 30561713
Ann Oncol. 2018 Nov 1;29(11):2175-2182
pubmed: 30202892
Ther Innov Regul Sci. 2020 Mar;54(2):462-467
pubmed: 32072587
JAMA. 2022 Dec 13;328(22):2252-2264
pubmed: 36511921
J Clin Oncol. 2015 Jul 1;33(19):2221-5
pubmed: 25940721
Trials. 2020 Jun 18;21(1):543
pubmed: 32552907
Clin Cancer Res. 2014 Aug 15;20(16):4210-7
pubmed: 25125258
J Med Ethics. 2017 Feb;43(2):114-117
pubmed: 27573151
BMC Med Ethics. 2014 Sep 05;15:66
pubmed: 25189994
Med Health Care Philos. 2016 Mar;19(1):125-39
pubmed: 26276449
Basic Clin Pharmacol Toxicol. 2015 Jul;117(1):44-51
pubmed: 25406995
Eur J Cancer. 2008 Jan;44(1):19-24
pubmed: 17890079
Ther Innov Regul Sci. 2021 May;55(3):612-618
pubmed: 33537954
Toxicol Pathol. 2009 Apr;37(3):363-71
pubmed: 19246571
J Clin Oncol. 2001 Jan 1;19(1):265-72
pubmed: 11134222
Trials. 2015 Nov 14;16:518
pubmed: 26566930
Front Pharmacol. 2018 Nov 19;9:1301
pubmed: 30510508
JNCI Cancer Spectr. 2019 Jun;3(2):pkz013
pubmed: 31206097
Ann Oncol. 2018 Mar 1;29(3):540-541
pubmed: 29415188
Cancer Chemother Pharmacol. 2014 Nov;74(5):1099-103
pubmed: 25245822
Transfus Sci. 1994 Dec;15(4):323-9
pubmed: 10155549
Therapie. 2009 May-Jun;64(3):149-59
pubmed: 19671427
EClinicalMedicine. 2023 May 25;60:102020
pubmed: 37261325
Clin Cancer Res. 2010 Mar 15;16(6):1710-8
pubmed: 20215546
Cochrane Database Syst Rev. 2012 Nov 14;11:MR000030
pubmed: 23152285
BMC Med. 2010 Mar 24;8:18
pubmed: 20334633
Contemp Clin Trials. 2021 Sep;108:106517
pubmed: 34320376
Clin Cancer Res. 2017 Dec 15;23(24):7440-7447
pubmed: 28733440
Stat Med. 2017 Jan 30;36(2):215-224
pubmed: 26928191
Eur J Clin Pharmacol. 2019 Apr;75(4):483-496
pubmed: 30569285
Oncologist. 2013;18(3):308-13
pubmed: 23457001
Control Clin Trials. 1995 Oct;16(5):319-30
pubmed: 8582150
Cancer. 2018 Aug;124(16):3290-3292
pubmed: 29975413
Clin Trials. 2008;5(5):478-85
pubmed: 18827040
Pharm Stat. 2017 Mar;16(2):100-106
pubmed: 28206702
Res Involv Engagem. 2020 Oct 14;6:61
pubmed: 33072399
J Biopharm Stat. 2019;29(2):271-286
pubmed: 30403559
Clin Cancer Res. 2010 Mar 15;16(6):1719-25
pubmed: 20215544
Crit Rev Oncol Hematol. 2018 May;125:78-83
pubmed: 29650280
Radiother Oncol. 2010 May;95(2):135-41
pubmed: 20338652
Clin Trials. 2019 Aug;16(4):339-344
pubmed: 30977390
Orphanet J Rare Dis. 2016 Oct 4;11(1):134
pubmed: 27716293
BMJ. 2016 Oct 24;355:i5239
pubmed: 27777223
Eur J Clin Pharmacol. 2020 Sep;76(9):1237-1243
pubmed: 32488334
J Biopharm Stat. 2006;16(5):579-604
pubmed: 17037260
Stat Med. 2017 Jul 20;36(16):2499-2513
pubmed: 28295513
Epilepsy Res. 2001 May;45(1-3):23-8; discussion 29-30
pubmed: 11461787
BMC Med Res Methodol. 2021 Apr 14;21(1):69
pubmed: 33853539
BMJ. 2014 Mar 07;348:g1687
pubmed: 24609605
BMC Med Res Methodol. 2019 Jan 18;19(1):18
pubmed: 30658575
PLoS Med. 2010 Feb 16;7(2):e1000217
pubmed: 20169112
Eur J Clin Pharmacol. 2010 Jul;66(7):647-53
pubmed: 20461363
Ther Innov Regul Sci. 2019 Mar;53(2):270-278
pubmed: 29759018
BMJ. 2022 Feb 7;376:e068177
pubmed: 35131744
Pharmaceut Med. 2019 Aug;33(4):261-268
pubmed: 31933186
J Pharmacokinet Pharmacodyn. 2018 Jun;45(3):383-397
pubmed: 29209907
Mov Disord. 2009 Oct 15;24(13):1893-901
pubmed: 19672990
J Clin Med Res. 2014 Jun;6(3):205-8
pubmed: 24734147
Neurorehabil Neural Repair. 2021 Aug;35(8):663-679
pubmed: 34085851
BMC Med Res Methodol. 2014 Jun 30;14:84
pubmed: 24980283
BMJ. 2020 Jun 17;369:m115
pubmed: 32554564
Therapie. 2004 May-Jun;59(3):329-47
pubmed: 15559187
Am J Clin Oncol. 2013 Apr;36(2):146-50
pubmed: 22314002
Pharm Stat. 2006 Jul-Sep;5(3):187-99
pubmed: 17080752
J Adv Nurs. 2000 Oct;32(4):1008-15
pubmed: 11095242
Ann Intern Med. 2013 Feb 5;158(3):200-7
pubmed: 23295957
Contemp Clin Trials. 2015 Jul;43:133-41
pubmed: 26012358
Stat Med. 2014 Sep 28;33(22):3815-29
pubmed: 24825779
BMC Med. 2018 Feb 28;16(1):29
pubmed: 29490655
Neuro Oncol. 2008 Aug;10(4):631-42
pubmed: 18559968
BMC Med Ethics. 2015 Jan 15;16:3
pubmed: 25591806
Nat Med. 2022 Jan;28(1):6-7
pubmed: 34992264
Contemp Clin Trials. 2021 Jun;105:106378
pubmed: 33823296
Clin Pharmacol Ther. 2018 Apr;103(4):564-566
pubmed: 29105746
Clin Pharmacol Ther. 2012 Mar;91(3):550-4
pubmed: 22318615
Eur J Cancer. 2021 Oct 14;158:85-98
pubmed: 34656816
Ann Oncol. 2015 Feb;26(2):300-6
pubmed: 25274616
Eur J Cancer. 2010 Nov;46(16):2870-8
pubmed: 20691584
Ann Oncol. 2018 Oct 1;29(10):2129-2134
pubmed: 30084933
Orphanet J Rare Dis. 2011 Nov 30;6:79
pubmed: 22129361
J Clin Epidemiol. 2014 Apr;67(4):401-9
pubmed: 24581294
Invest New Drugs. 2017 Dec;35(6):827-833
pubmed: 28905282
Br J Clin Pharmacol. 2017 Dec;83(12):2807-2812
pubmed: 28975652
J Clin Oncol. 2017 Nov 20;35(33):3781-3787
pubmed: 28968169
Biometrics. 1977 Mar;33(1):159-74
pubmed: 843571
Eur J Pharm Sci. 2001 May;13(2):115-22
pubmed: 11297895
Eur J Clin Pharmacol. 2017 Apr;73(4):409-416
pubmed: 28064353
N Engl J Med. 2016 May 26;374(21):2001-3
pubmed: 27074059
Ann Oncol. 1996 Aug;7(6):567-73
pubmed: 8879369
Clin Transl Sci. 2019 Jan;12(1):6-19
pubmed: 30048046
Clin Pharmacol Ther. 2021 Oct;110(4):1025-1037
pubmed: 34050933
J Clin Oncol. 2000 Jan;18(2):429-36
pubmed: 10637259
Biol Blood Marrow Transplant. 2001;7(8):414-32
pubmed: 11569887
Am Soc Clin Oncol Educ Book. 2021 Jun;41:e133-e144
pubmed: 34061563